• 1. Fe3O4 nanosphere@microporous organic networks: enhanced anode performances in lithium ion batteries through carbonization?
  Byungho Lim,Jaewon Jin,Jin Yoo,Seung Yong Han,Kyeongyeol Kim,Sungah Kang,Nojin Park,Sang Moon Lee,Hae Jin Kim,Seung Uk Son Chem. Commun., 2014,50, 7723-7726
• 2. Exchangeability of amino acid residues with similar physicochemical properties in coiled-coil interactions?
  Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088
• 3. Emerging investigator series: first-principles and thermodynamics comparison of compositionally-tuned delafossites: cation release from the (001) surface of complex metal oxides?
  Joseph W. Bennett,Diamond T. Jones,Blake G. Hudson,Joshua Melendez-Rivera,Robert J. Hamers,Sara E. Mason Environ. Sci.: Nano, 2020,7, 1642-1651
• 4. Exceptional activity of sub-nm Pt clusters on CdS for photocatalytic hydrogen production: a combined experimental and first-principles study?
  Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064
• 5. Exchanged ligands on the surface of a giant cluster: [(MoO3)176(H2O)63(CH3OH)17Hn](32 – n)–
  Chem. Commun., 1998, 1501-1502

Introduction to 2-(2,6-dimethylphenyl)ethanimidamide (CAS No. 374064-82-1)

2-(2,6-dimethylphenyl)ethanimidamide, identified by its Chemical Abstracts Service (CAS) number 374064-82-1, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical chemistry and bioorganic research. This compound belongs to the class of amides, characterized by a carbonyl group (C=O) bonded to a nitrogen atom (N), which plays a pivotal role in its reactivity and potential biological activity. The presence of a phenyl ring substituted with two methyl groups at the 2 and 6 positions enhances its structural stability and influences its electronic properties, making it a promising candidate for further investigation in medicinal chemistry.

The structure of 2-(2,6-dimethylphenyl)ethanimidamide is composed of an ethanimidamide moiety attached to a 2,6-dimethylphenyl group. The ethanimidamide moiety consists of an acetylene-like backbone with an amide functional group, which is known for its versatility in drug design due to its ability to interact with biological targets through hydrogen bonding and hydrophobic interactions. The 2,6-dimethylphenyl group contributes to the compound's lipophilicity and can influence its solubility and metabolic stability, factors that are critical in drug development.

In recent years, there has been a surge in research focused on developing novel therapeutic agents that leverage the unique properties of amide-based compounds. Amides are widely recognized for their role as bioisosteres, allowing chemists to modify existing drug molecules to improve pharmacokinetic profiles while maintaining or enhancing biological activity. The incorporation of aromatic rings, such as the 2,6-dimethylphenyl moiety in 2-(2,6-dimethylphenyl)ethanimidamide, is particularly noteworthy as it can serve as a scaffold for designing molecules with enhanced binding affinity and selectivity towards specific biological targets.

One of the most compelling aspects of 2-(2,6-dimethylphenyl)ethanimidamide is its potential application in the development of small-molecule inhibitors for various therapeutic targets. The compound's structure suggests that it may interact with enzymes or receptors involved in critical biological pathways. For instance, the amide group could serve as a hydrogen bond acceptor or donor, facilitating interactions with polar residues in protein active sites. Additionally, the phenyl ring can engage in π-stacking interactions with aromatic residues, further stabilizing the binding interface.

Recent studies have highlighted the importance of structure-activity relationships (SAR) in designing effective drug candidates. By systematically modifying the substituents on the phenyl ring and the amide moiety of 2-(2,6-dimethylphenyl)ethanimidamide, researchers can fine-tune its biological activity. For example, replacing one of the methyl groups with an electron-withdrawing group might enhance binding affinity by increasing the compound's ability to interact with negatively charged residues in the target protein. Conversely, introducing hydrophilic groups could improve solubility and reduce off-target effects.

The pharmaceutical industry has increasingly recognized the value of bioisosteric replacements in drug discovery. The ethanimidamide moiety in 2-(2,6-dimethylphenyl)ethanimidamide serves as an excellent example of how bioisosterism can be leveraged to develop novel compounds with improved properties. By replacing traditional amide groups with ethanimidamides, chemists can achieve enhanced metabolic stability while maintaining or even improving biological activity. This approach has been successfully applied in various drug classes, including kinase inhibitors and antiviral agents.

Advances in computational chemistry have further accelerated the discovery process for compounds like 2-(2,6-dimethylphenyl)ethanimidamide. Molecular modeling techniques allow researchers to predict how different structural modifications will affect binding affinity and selectivity before conducting expensive experimental trials. By integrating these computational methods with experimental data, scientists can rapidly optimize lead compounds and identify promising candidates for further development.

The synthesis of 2-(2,6-dimethylphenyl)ethanimidamide presents unique challenges due to its complex structure. However, modern synthetic methodologies have made it increasingly feasible to construct such molecules efficiently. Techniques such as palladium-catalyzed cross-coupling reactions and transition-metal-mediated transformations have enabled chemists to build intricate organic frameworks with high precision. These advances have not only facilitated the synthesis of 2-(2,6-dimethylphenyl)ethanimidamide but also opened new avenues for exploring related compounds.

In conclusion, 2-(2,6-dimethylphenyl)ethanimidamide (CAS No. 374064-82-1) represents a fascinating subject of study in pharmaceutical chemistry. Its unique structure and potential biological activity make it a valuable candidate for further investigation into drug discovery and development. As research continues to uncover new applications for this compound and related molecules, future studies will likely focus on optimizing its pharmacological properties and exploring its therapeutic potential across various disease areas.

• 5504-24-5(2-Phenylacetamidine)
• 2498-46-6(2-phenylacetamidine;hydrochloride)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)